

**Supplemental Table 1: Baseline Characteristics of subjects on cardiac medications**

	ACEI and/or ARB			Calcium Channel Blocker		
	Yes (n=785)	No (n= 2679)	P value	Yes (n=419)	No (n=3045)	P value
Age (years)	65.5 (7.9)	62.7 (8.6)	<0.001	65.7 (7.7)	63.1 (8.6)	<0.001
Gender,female,%	324 (41.3)	1213 (45.3)	0.047	185 (44.2)	1352 (44.4)	0.924
Race,African American, %	150 (19.1)	615 (23.0)	0.022	108 (25.8)	657 (21.6)	0.052
BMI (kg/m <sup>2</sup> )	29.9 (6.6)	27.5 (6.1)	<0.001	29.6 (6.6)	27.9 (6.2)	<0.001
Packyears of smoking	56.9 (30.5)	52.1 (26.5)	<0.001	56.2 (30.7)	52.8 (27.0)	0.017
FEV <sub>1</sub> (L)	1.42 (0.57)	1.45 (0.64)	0.200	1.38 (0.59)	1.45 (0.63)	0.023
FEV <sub>1</sub> % predicted	50.4 (16.7)	50.3 (18.2)	0.873	49.6 (17.6)	50.4 (17.9)	0.401
FEV <sub>1</sub> /FVC	0.50 (0.13)	0.49 (0.13)	0.077	0.49 (0.13)	0.50 (0.13)	0.558
GOLD Stage,%			0.052			0.730
II	425 (54.1)	1406 (52.5)		214 (51.1)	1617 (53.1)	
III	259 (33.0)	833 (31.1)		138 (32.9)	954 (31.3)	
IV	101 (12.9)	440 (16.4)		67 (16.0)	474 (15.6)	
Home Oxygen therapy,%	231 (29.4)	724 (27.0)	0.185	134 (32.0)	821 (27.0)	0.031
Severe exacerbation in prior year,%	172 (21.9)	605 (22.6)	0.691	113 (27.0)	664 (21.8)	0.018
Asthma,%	222 (28.3)	707 (26.4)	0.293	137 (32.7)	792 (26.0)	0.004
Coronary artery disease,%	231 (29.4)	334 (12.5)	<0.001	116 (27.7)	449 (14.7)	<0.001
Peripheral vascular disease,%	41 (5.2)	79 (2.9)	0.002	24 (5.7)	96 (3.2)	0.007
Cerebrovascular disease,%	59 (7.5)	147 (5.5)	0.035	31 (7.4)	175 (5.7)	0.180
Congestive heart failure,%	73 (9.3)	108 (4.0)	<0.001	42 (10.0)	139 (4.6)	<0.001
Hypertension,%	686 (87.4)	1070 (40.0)	<0.001	373 (89.0)	1383 (45.4)	<0.001
Diabetes mellitus,%	163 (20.8)	311 (11.6)	<0.001	107 (25.5)	274 (9.0)	<0.001
Emphysema (%LAA<950 <sub>insp</sub> )	11.5 (11.7)	13.3 (12.9)	0.001	13.4 (12.6)	12.9 (12.6)	0.499
Gas trapping (%LAA<856 <sub>exp</sub> )	37.2 (19.7)	39.5 (21.0)	0.014	39.6 (20.2)	38.9 (20.8)	0.576
Wallarea% segmental	62.6 (3.0)	62.7 (3.0)	0.547	62.6 (2.7)	62.7 (3.1)	0.453
CAC	350.2 (529.1)	211.6 (395.4)	<0.001	274.8 (408.2)	238.4 (435.9)	0.126
MMRC	2.2 (1.4)	2.1 (1.4)	0.099	2.2 (1.4)	2.1 (1.4)	0.074
SGRQ	41.4 (21.0)	40.4 (22.1)	0.272	42.0 (21.7)	40.5 (21.9)	0.192
6MWD (m)	335 (130)	356 (133)	<0.001	329 (127)	354 (133)	<0.001
BODE	3.0 (2.0)	2.9 (2.1)	0.575	3.0 (2.0)	2.9 (2.1)	0.186

ACEI = Angiotensin Converting Enzyme Inhibitor. ARB = Angiotensin Receptor Blocker. CCB = Calcium Channel Blocker. BMI = Body Mass Index. FEV<sub>1</sub> = Forced Expiratory Volume in the first second. FVC = Forced Vital Capacity. GOLD = Global Initiative for Chronic Obstructive Lung Disease. %LAA<950<sub>insp</sub> = %Low Attenuation Area below a threshold of -950 Hounsfield Units at end inspiration. %LAA<856<sub>exp</sub> = %Low Attenuation Area below a threshold of -856 Hounsfield Units at end tidal expiration. Wallarea% = Bronchial wall area at segmental level. CAC = Coronary artery calcification as measured by Agatston score. MMRC = Modified Medical Research Council Dyspnea Scale. SGRQ = St. George's Respiratory Questionnaire. 6MWD = Six Minute Walk Distance. BODE = Body Mass Index, Airflow Obstruction, Dyspnea, and Exercise Capacity Index.